ArticleMolecular therapy. Methods & clinical development2021

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.

Biping Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.